Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Sunesis Pharmaceuticals"
|Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
|Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
|Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
|Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
|Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
|Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
|Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
|Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
|Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
|Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
|Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
|Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
|Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
|Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
|Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
|Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
|Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy